Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now full pipeline small index

Dyspareunia: full-pipeline trial registry

2 of 11 indexed Dyspareunia trials are currently recruiting.

Corpus placement: #1,577 of 28,707 conditions by registered trial count.

11 US clinical trials · 2 currently recruiting · #1,577 of 28,707 conditions by registered trial count

Dyspareunia: 11 US clinical trials tracked, 2 recruiting.

Dyspareunia is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is San Diego Sexual Medicine, running 1 of these trials.

Enrollment posture brief

Registry condition dyspareunia

OPEN 2 | RECR 18% | LATE 2 | EARLY 2 | RANK #1577 | SPON 1

Nearest open-share peer: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome (18% recruiting · 22 trials)

Acute Pancreatitis81.8%Acute Stroke45.5%Acquired Brain Injury36.4%Dyspareunia (this)18%Acute Lung Injury9.1%
Open-enrollment share among volume-matched conditions near Dyspareunia

Dyspareunia lists 2 open slots (18% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Dyspareunia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Dyspareunia is recruiting below its size-band peers.

    2 of 11 indexed trials (18.2%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Dyspareunia trials is spread across many organizations.

    San Diego Sexual Medicine accounts for 1 of 11 trials (9.1%). 11 distinct sponsors appear on at least one study for this condition label.

  3. Most Dyspareunia trials plan to enrol fewer than 100 people.

    Median target enrolment is 50 among the 11 trials that report a genuine target (sentinel values excluded). 9 of those (81.8%) plan for fewer than 100 participants.

  4. Dyspareunia research is mostly interventional.

    10 interventional and 1 observational studies make up this index (90.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 21Phase 31Phase 41

Open and recent trials

11 total, page 1 of 1

RECRUITING NA 60 participants

VIBRating vs Traditional Therapy for Treatment of ENTry Dyspareunia

Medstar Health Research Institute

NCT06840314

RECRUITING NA 20 participants

Pre-Rehabilitation for Female Patients Undergoing Pelvic Radiotherapy

Indiana University

NCT06059586

ACTIVE NOT RECRUITING 200 participants

Prospective on Market Patient-reported Outcomes for Milli

Materna Medical

NCT06397885

COMPLETED Phase 2 203 participants

A Safety and Efficacy Study of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy

Warner Chilcott

NCT02670785

COMPLETED NA 66 participants

Fractional CO2 Laser Therapy for Survivors of Breast Malignancies

Ohio State University Comprehensive Cancer Center

NCT03307044

COMPLETED NA 60 participants

Hybrid Fractional Laser for Symptoms of Genitourinary Syndrome of Menopause

Sciton

NCT03178825

COMPLETED Phase 3 50 participants

Therapy to Prevent Sexual Pain in Breast Cancer Survivors

OHSU Knight Cancer Institute

NCT01539317

COMPLETED NA 36 participants

Acupuncture for the Treatment of Vulvodynia

Schlaeger, Judith M., CNM, LAc, PhD

NCT02197429

COMPLETED Phase 4 18 participants

Changes to Vulva, Vestibule, Urethral Meatus and Vagina 20 Weeks Post Daily Prasterone in Women With Dyspareunia

San Diego Sexual Medicine

NCT03568604

COMPLETED Early Phase 1 12 participants

Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy

Creighton University

NCT01697345

COMPLETED NA 6 participants

Acupuncture for Vulvodynia: A Pre-pilot Study

University of Illinois at Chicago

NCT02704234

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1
Phase 3 1
Phase 4 1

Named interventions

Most-linked intervention names on Dyspareunia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Hybrid Fractional Laser Device
1 trials
Topical liquid lidocaine Drug
1 trials
Estradiol Vaginal Capsule (EVC) Drug
1 trials
Placebo Acupuncture Other
1 trials
Active Acupuncture Other
1 trials
Laser Therapy Procedure
1 trials
Milli Vaginal Dilator Device
1 trials
Pelvic floor therapy Device
1 trials

US sites by state

Facility locations filed on Dyspareunia trials. A trial with sites in several states counts in each.

California 4 trials
Virginia 2 trials
Texas 2 trials
Ohio 2 trials
North Carolina 2 trials
Illinois 2 trials
Florida 2 trials
Washington 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Dyspareunia page

11 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Dyspareunia condition card totals 11 registered trials; most-linked intervention Hybrid Fractional Laser; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.